9 results about "Salmonella enterica" patented technology

The present invention relates to immunogenic compositions comprising antigens derived from Salmonella enterica serotype tiphimurium (S. Typhimurium), Salmonella enterica serotype enteritidis (S. Enteritidis), and Salmonella enterica serotype typhi (S. Typhi). The present invention further relates to methods and compositions comprising GMMA for boosting the immune response to the S. Typhi antigen, vaccines and methods comprising immunogenic compositions, and the use of immunogenic compositions.

An antimicrobial peptide having an amino acid sequence selected from SEQ ID NOs: 2-12 is provided. The antimicrobial peptide has antimicrobial activity against Gram-negative bacteria, Campylobacter jejuni, Escherichia coli, Salmonella enterica subsp. enterica serovar typhimurium, Salmonella enterica subsp. enterica serovar choleraesuis, Klebsiella pneumonica, and / or Enterobacter cloacae. A composition, pharmaceutical composition, food additive, cosmetic composition, or hygine product having an antimicrobial peptide including an amino acid sequence selected from SEQ ID NOs: 2-12 is also provided. A method of treating an infectious disease caused by bacteria including a step of administering a pharmaceutical composition having the antimicrobial peptide as an active ingredient is also provided.

The present invention relates to a novel bacteriophage OPT-SALO1 with specific killing ability for Salmonella enterica, an antibiotic composition comprising the bacteriophage, a composition for adding to a feed, a feed, a disinfectant or a cleaning agent, and a method for preventing or treating infectious diseases caused by Salmonella enterica comprising a step of administering the bacteriophage to a subject.

Technologies for the prevention and / or treatment of Salmonella infections.

The invention provides a primer probe combination, a kit, a nucleic acid detection method and application, and relates to the technical field of biochemical detection. The primer probe combination comprises a first primer pair and a first probe, wherein the first primer pair and the first probe are used for specifically amplifying pseudomonas aeruginosa; the second primer pair and the second probe are used for specifically amplifying enterococcus; the third primer pair and the third probe are used for specifically amplifying staphylococcus aureus; the fourth primer pair and the fourth probe are used for specifically amplifying the salmonella enterica. According to the primer and probe combination, a specific nucleotide sequence is utilized, efficient and accurate recognition of pseudomonas aeruginosa, enterococcus, staphylococcus aureus and salmonella enterococcus is achieved in a complex intestinal environment, and non-specific interference is effectively avoided; meanwhile, synchronous quantitative detection of four pathogens is supported, the detection efficiency is remarkably improved, and an accurate and sensitive detection means is provided for rapid clinical evaluation of flora conditions.

The present invention relates to immunogenic compositions comprising Salmonella enterica paratyphoid A serotype outer membrane vesicles (OMV), vaccines comprising said immunogenic compositions, and methods and uses of said immunogenic compositions. The invention also relates to Salmonella paratyphi A bacteria comprising the modified lipid A.

The invention relates to a beta-hairpin defense peptide as well as a derivative and application thereof, the beta-hairpin defense peptide is Jz-Def, and the amino acid sequence of the beta-hairpin defense peptide is as shown in SEQ ID No.1, specifically as follows: YCRRVCGRKRCFTYCRGK. The derivative of the beta-hairpin defensive peptide is defensive peptide Jz-M3, and the amino acid sequence of the defensive peptide Jz-M3 is as shown in SEQ ID No.2, specifically as follows: RWCRRFCRNGRCVRYCWR. The invention further discloses application of the beta-hairpin defense peptide and / or the derivative of the beta-hairpin defense peptide in preparation of bacteriostatic and bactericidal drugs or products. The beta-hairpin defensive peptide Jz-Def and the derivative defensive peptide Jz-M3 of the beta-hairpin defensive peptide Jz-Def and the derivative defensive peptide Jz-M3 of the beta-hairpin defensive peptide Jz-Def can kill clinical drug-resistant bacteria gram-positive pathogenic bacteria, gram-negative pathogenic bacteria and fungi at The bacillus amyloliquefaciens has strong antibacterial and bactericidal properties on providencia chinensis and other pathogenic bacteria in aquaculture and enterococcus faecalis, salmonella enterica and other putrefying bacteria in food, has very strong broad-spectrum antibacterial properties, has very strong high-temperature stability in antibacterial and bactericidal properties, has low hemolytic activity, and can be used for preparing the bacillus amyloliquefaciens. The composition has no obvious inhibiting and killing effect on phytobacterium and saccharomyces cerevisiae, and is high in safety.

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gram-negative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acineto-bacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.

A method for increasing Salmonella outer membrane vesicle production includes the following steps: constructing knockout... tolR Recombinant Salmonella strains containing genes from wild-type Salmonella enterica SDC-11 tolR Obtained after gene knockout; will knockout tolR Recombinant Salmonella strains containing the gene were cultured in LB medium supplemented with glycine at 30–39°C for 2–24 h, and then outer membrane vesicles were collected. This invention constructs a knockout... tolR Salmonella strain sdc-11Δ tolR The OMV production was increased by 1.6 times. Based on this, the culture conditions of the strain were optimized by adding glycine to the culture medium, which further increased the OMV production by 8.8 times, confirming that culturing at 37℃ for 18 h was the optimal production condition. Compared with the wild-type strain sdc-11, the shape and particle size of the OMVs secreted by the recombinant strain under the above conditions were not significantly different.